Latest Breaking News On - Epidarex capital - Page 1 : vimarsana.com

Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration

Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomFrancesca simoncelloSue charlesStephen myattSteve myattLuca cassettaJeffrey pollardFounderof macomicsMacomics ltdUniversity of milanLaboratory of profItalian association for cancer researchCaribou propertyCancer researchInstitute of molecular oncology

Topas Therapeutics Appoints Hugo Fry as CEO

Topas Therapeutics Appoints Hugo Fry as CEO
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofAlison opalkoSanofi pasteurErichf greinerUniversity of salfordLondon business schoolImbria pharmaceuticalsBoehringer ingelheim venture fundDuke universityTrophic communicationsIndustrial affairsHugo fryChief executiveExecutive chairmanChief commercial officer

Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion

Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesTim wilsonDavid chiswellAndrew calamZwei rohstoff chancenNick robbinsSimon conwayAshley nagleDave chiswellLonza biologicsExperte carsten storkElizabeth hardakerUniversity of leedsBusiness development at remedybio

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofSue charlesJonathan savidgeKynos therapeutics ltdUniversity of edinburghIp groupTherapeutics ltdInnovate united kingdomKynos therapeuticsEpidarex capitalScottish enterpriseInnovate united

Kynos successfully completes initial phase of drug trials

Kynos Therapeutics has successfully completed the first tests in humans of its leading drug candidate to reduce tissue damage caused by inflammation

City ofUnited kingdomIp groupUniversity of edinburghDamian moleEpidarex capitalScottish enterpriseInnovate united